US Stock Futures Drop Ahead Of Consumer Sentiment Report

Loading...
Loading...
Pre-open movers
US stock futures traded lower in early pre-market trade, ahead of economic data. The Reuter's/University of Michigan's consumer sentiment index for June will be released at 9:55 a.m. ET. Futures for the Dow Jones Industrial Average dropped 30 points to 16,732.00, while the Standard & Poor's 500 index futures fell 4.80 points to 1,943.90. Futures for the Nasdaq 100 index declined 6.25 points to 3,811.25.
A Peek Into Global Markets
European markets were mixed today, with the Spanish Ibex Index dropping 0.12%, STOXX Europe 600 Index declining 0.05%. German DAX 30 index fell 0.02%, French CAC 40 Index rose 0.09% and London's FTSE 100 Index gained 0.07%. French consumer spending increased 1% in May from April, while producer price index dropped 0.5% in May versus April. Spanish consumer price index remained unchanged in June, versus a 0.2% gain in May. UK's consumer confidence index climbed to 1 in June. In Asian markets, Japan's Nikkei Stock Average fell 1.39%, Hong Kong's Hang Seng Index surged 0.10%, China's Shanghai Composite Index declined 0.11% and India's BSE Sensex rose 0.15%. Japan's unemployment declined to 3.5% in May.
Broker Recommendation
Analysts at Jefferies upgraded Manitowoc Company
MTW
from “underperform” to hold.” The target price for Manitowoc has been raised from $24 to $33. Manitowoc's shares closed at $29.71 yesterday.
Breaking news
  • Commercial Metals Co CMC reported a rise in its fiscal third-quarter profit. Commercial Metals posted a quarterly profit of $23.6 million, or $0.20 per share, versus a year-ago profit of $19 million, or $0.16 per share. To read the full news, click here.
  • Karyopharm Therapeutics KPTI announced Thursday the pricing of its underwritten public offering of 2,647,247 shares of its common stock at a price of $42.50 per share before underwriting discounts. To read the full news, click here.
  • Bristol-Myers Squibb Company BMY today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza® (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults. To read the full news, click here.
  • Regeneron Pharmaceuticals REGN today announced that EYLEA® (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to diabetic macular edema (DME). To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsJefferiesUS stock future
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...